Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47658 | 0.81 | PRMT3 (0.32) | — | |
| SCHEMBL18735636 | 0.72 | KMT2A (0.36) | CYP2C19CA12CA2CA9 | |
| SCHEMBL13667603 | 0.69 | — | — | |
| SCHEMBL18251218 | 0.69 | CA12 (0.38) | CA12CA2CA3CA4CA6 | |
| SCHEMBL20806106 | 0.68 | GAA (0.40) | — | |
| SCHEMBL8137111 | 0.68 | RIPK1 (0.41) | CYP2C19CA12CA2CA3CA4 | |
| SCHEMBL19069324 | 0.67 | CYP2C19 (0.44) | CYP2C19 | |
| SCHEMBL8908706 | 0.67 | POLB (0.30) | — | |
| SCHEMBL26723220 | 0.67 | POLB (0.30) | — | |
| SCHEMBL16812985 | 0.67 | CA12 (0.45) | CA12CA2CA3CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2015-02-26 | — | — | US | disclosed |
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CYP2C19 212/4885CA12 624/4885CA2 887/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | CYP2C19 212/4885CA12 624/4885CA2 887/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CYP2C19 212/4885CA12 607/4885CA2 848/4885 |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | CYP2C19 98/4885CA12 3101/4885CA2 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.